ClinicalTrials.gg
CompletedNCT03808493Updated Apr 7, 2020Results posted

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

A Phase 1 interventional study of TAK-438 OD and TAK-438 in Japanese Healthy Adult Male, sponsored by Takeda. Completed at 1 site in Japan. Open to male participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the BE of single oral dose of TAK-438 OD 20 milligram (mg) tablet without water and TAK-438 20 mg tablet with water (Study 1), and TAK-438 OD 20 mg tablet with water and TAK-438 20 mg tablet with water (Study 2) in Japanese healthy adult male participants.

Read the detailed description

The drug being tested in this study is called TAK-438 OD tablet. TAK-438 OD tablet is being tested in Japanese healthy adult men. This study will evaluate bioequivalence of single oral dose of TAK-438 OD 20 mg tablet without water and TAK-438 20 mg tablet with water (Study 1), and TAK-438 OD 20 mg tablet with water and TAK-438 20 mg tablet with water (Study 2).

The study will enroll up to 144 participants in total (Study 1 + 2). In Study 1 and 2, participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups;

Study 1:

  • TAK-438 OD 20 mg tablet without water (Period 1) + TAK-438 20 mg tablet with water (Period 2)
  • TAK-438 20 mg tablet with water (Period 1) + TAK-438 OD 20 mg tablet without water (Period 2)

Study 2:

  • TAK-438 OD 20 mg tablet with water (Period 1) + TAK-438 20 mg tablet with water (Period 2)
  • TAK-438 20 mg tablet with water (Period 1) + TAK-438 OD 20 mg tablet with water (Period 2)

This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 11 days. Participants will make two visits to the clinic and be hospitalized for four days each in Periods 1 and 2.

02

Conditions studied

  • Japanese Healthy Adult Male

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, form prior to the initiation of any study procedures.
  3. The participant is a healthy Japanese adult male, aged 20 to 60 years, inclusive, at the time of informed consent.
  4. The participant weighs at least 50 kilogram (kg) and has a (BMI) from 18.5 to 25.0 kilogram per square meter (kg/m\^2), inclusive at Screening.
  5. The participant must be a current nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months prior to the start of study drug administration in Period 1.
  6. The participant must be judged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead (ECG), and vital sign measurements performed at the Screening Visit and prior to the start of study drug administration in Period 1.

Exclusion criteria

Exclusion Criteria:

  1. The participant has received any compound within 16 weeks (112 days) prior to the start of study drug administration in Period 1.
  2. The participant has received TAK-438 in a previous clinical study or as a therapeutic agent.
  3. The participant is an immediate family member of or a study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  4. The participant has uncontrolled, neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or endocrine disease or other abnormality (other than the disease being studied), which may impact the ability of the participant to participate in the study or potentially confound its results.
  5. The participant has to any component of TAK-438 OD tablet or TAK-438 tablet.
  6. The participant has a positive urine drug result for drugs of abuse at Screening.
  7. The participant has a history of drug or alcohol abuse within 2 years prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  8. The participant has taken any excluded medication, supplements, or food products during the specified time periods.
  9. The participant has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
  10. The participant has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  11. The participant has a positive test result for virus surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody/antigen, or serological reactions for syphilis at Screening.
  12. The participant has poor peripheral venous access.
  13. The participant has undergone whole blood collection of at least 200 milliliter (mL) within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of study drug administration in Period 1.
  14. The participant has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to the start of study drug administration in Period 1.
  15. The participant has undergone blood component collection within 2 weeks (14 days) prior to the start of study drug administration in Period 1.
  16. The participant has a Screening or Check-in (Day -1) that was abnormal (clinically significant).
  17. The participant has abnormal Screening laboratory values that suggest a clinically significant underlying disease or participant with the following laboratory abnormalities: (ALT) or aspartate aminotransferase (AST) above the (ULN).
  18. The participant who, in the opinion of the investigator or sub-investigator, is unlikely to comply with the protocol or is unsuitable for any other reason.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Study 1, TAK-438 OD + TAK-438

    One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).

    Drug: TAK-438 OD · Drug: TAK-438

  • Experimental
    Study 1, TAK-438 + TAK-438 OD

    One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).

    Drug: TAK-438 OD · Drug: TAK-438

  • Experimental
    Study 2, TAK-438 OD + TAK-438

    One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).

    Drug: TAK-438 OD · Drug: TAK-438

  • Experimental
    Study 2, TAK-438 + TAK-438 OD

    One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).

    Drug: TAK-438 OD · Drug: TAK-438

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F)

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

  2. Cmax: Maximum Observed Plasma Concentration for TAK-438F

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

Secondary outcomes

  1. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

  2. Tmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

  3. MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

  4. λz: Terminal Disposition Phase Rate Constant for TAK-438F

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose

07

Results

Posted Mar 24, 2020

Participant flow

Participants took part in the study at 1 investigative site in Japan from 30 January 2019 to 12 March 2019.

Participant flow — Overall Study
MilestonePilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg
Started12121212
Completed12121212
Not completed0000

Outcome measures

PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F)
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F)
hour*nanogram per milliliter (h*ng/mL)Pilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F)190.2 ± 67.984194.3 ± 67.693201.6 ± 81.799201.2 ± 75.813
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: -0.0211 · 90% CI -0.0752 to 0.0329
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: 0.0019 · 90% CI -0.0778 to 0.0815
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-438F
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-438F
nanogram per milliliter (ng/mL)Pilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
Cmax: Maximum Observed Plasma Concentration for TAK-438F22.62 ± 7.815224.26 ± 8.067621.85 ± 7.728623.70 ± 8.5998
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: -0.0698 · 90% CI -0.1404 to 0.0008
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: -0.0811 · 90% CI -0.1658 to 0.0036
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Geometric mean · h*ng/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F
h*ng/mLPilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F192.5 ± 68.755196.4 ± 68.436204.3 ± 83.014203.6 ± 77.630
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: -0.0199 · 90% CI -0.0731 to 0.0333
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: 0.0035 · 90% CI -0.0760 to 0.0830
SecondaryTmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Median · hour
Tmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F
hourPilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
Tmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F2.000 (1.00 to 4.00)1.750 (1.00 to 3.00)2.000 (1.00 to 4.00)2.000 (1.00 to 4.00)
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: 0.1902 · 90% CI 0.0199 to 0.3605
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: 0.2142 · 90% CI 0.0558 to 0.3725
SecondaryMRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Mean · hour
MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F
hourPilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F9.576 ± 1.18079.258 ± 0.911259.831 ± 1.35069.544 ± 1.4121
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: 0.0311 · 90% CI 0.0022 to 0.0599
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: 0.0306 · 90% CI -0.0003 to 0.0616
Secondaryλz: Terminal Disposition Phase Rate Constant for TAK-438F
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Reported as:
Mean · per hour (1/hour)
λz: Terminal Disposition Phase Rate Constant for TAK-438F
per hour (1/hour)Pilot BE Study 1: TAK-438 OD 20 mgPilot BE Study 1: TAK-438 20 mgPilot BE Study 2: TAK-438 OD 20 mgPilot BE Study 2: TAK-438 20 mg
λz: Terminal Disposition Phase Rate Constant for TAK-438F0.1014 ± 0.0144410.09903 ± 0.0112690.09807 ± 0.0130210.09989 ± 0.016690
Statistical analysis
  • Pilot BE Study 1: TAK-438 OD 20 mg vs Pilot BE Study 1: TAK-438 20 mg · Ls-means difference: 0.0209 · 90% CI -0.0112 to 0.0530
  • Pilot BE Study 2: TAK-438 OD 20 mg vs Pilot BE Study 2: TAK-438 20 mg · Ls-means difference: -0.0135 · 90% CI -0.0508 to 0.0238

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are adverse events (AE) that started after the first dose of study drug until Day 3 in Period 2 (up to Day 13). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pilot BE Study 1: TAK-438 OD 20 mg0/24 (0%)0/24 (0%)0/24 (0%)
Pilot BE Study 1: TAK-438 20 mg0/24 (0%)0/24 (0%)0/24 (0%)
Pilot BE Study 2: TAK-438 OD 20 mg0/24 (0%)0/24 (0%)0/24 (0%)
Pilot BE Study 2: TAK-438 20 mg0/24 (0%)0/24 (0%)0/24 (0%)

Baseline characteristics

The safety analysis set was defined as all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Mean22.1 ± 3.8726.0 ± 6.7426.5 ± 7.1926.0 ± 6.7625.1 ± 6.34
Sex: Female, Male
Sex: Female, Male(Participants)Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Female00000
Male1212121248
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Count of participants————0
Region of Enrollment
Region of Enrollment(Participants)Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Japan1212121248
Height
Height(centimeter (cm))Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Mean171.8 ± 4.00170.0 ± 6.52173.9 ± 4.32172.2 ± 6.94172.0 ± 5.59
Weight
Weight(kilogram (kg))Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Mean59.83 ± 4.67260.95 ± 4.72063.29 ± 4.86065.44 ± 6.71662.38 ± 5.586
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Mean20.28 ± 1.81721.15 ± 1.82920.94 ± 1.78122.03 ± 1.04321.10 ± 1.718
Caffeine Consumption
Caffeine Consumption(Participants)Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mgPilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mgPilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mgTotal
Had caffeine consumption214411
Had no caffeine consumption10118837

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Sekino Clinical Pharmacology Clininc
    Toshima-ku, Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Mar 2019, 1 month.

Results were first posted in Mar 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2019
First posted
Jan 17, 2019
StartActual
Jan 30, 2019
Primary completionActual
Mar 12, 2019
CompletionActual
Mar 12, 2019
Results first posted
Mar 24, 2020
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03808493
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 17, 2019
Start date
Jan 30, 2019
Primary completion
Mar 12, 2019
Completion
Mar 12, 2019
Results posted
Mar 24, 2020
Last update
Apr 7, 2020

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion